基于放疗前后外周血DNA甲基化的头颈癌结局分层
研究对115例非转移性头颈鳞癌患者放疗前1周和放疗后1个月的外周血进行甲基化分析,随机分为发现队列和验证队列,构建甲基化风险评分(MRS)。高MRS(前三分之一)在发现队列和验证队列中均独立预测更差的无复发生存和总生存。
要点
- 放疗前1周和放疗后1个月外周血DNA甲基化变化可构建MRS。
- 高MRS(前三分之一)独立预测更差的无复发生存和总生存。
- MRS在发现队列和验证队列中均得到验证。
核心结论
- 研究成功训练并验证了放疗前后外周血DNA甲基化特征,可对头颈鳞癌患者进行结局分层,提示基因组学指导监测和巩固治疗的潜力。
研究设计与样本
- 研究纳入115例非转移性头颈鳞癌患者,放疗前1周和放疗后1个月采集外周血进行甲基化分析,患者按1:1随机分为发现队列和验证队列,在发现队列中用Cox回归评估全基因组甲基化变化与无复发生存及总生存的关联,并构建甲基化风险评分(MRS),在发现队列和验证队列中分别评估其预后价值。
主要发现
- 2013年12月至2018年9月,115例患者参与研究;人乳头瘤病毒阴性状态、口腔癌、胃造瘘管置入及放疗前较高中性粒细胞计数与更短的无复发生存和总生存相关(P < .05)。
- MRS所包含甲基化位点的下游基因包括HIF1A、SF1、LGALS9和FUT5,参与缺氧反应、血细胞成熟和免疫调节。
- 在发现队列中,高MRS(前三分之一)与更差的无复发生存显著相关(HR,7.1;95%CI,1.4-35.5;P = .016),与更差的总生存显著相关(HR,15.9;95%CI,1.6-153.6;P = .017),且独立于上述风险因素。
- 在验证队列中,高MRS同样独立预测更差的无复发生存(HR,10.2;95%CI,2.4-43.4;P = .002)和总生存(HR,3.7;95%CI,1.3-10.4;P = .015)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Established prognostic factors for head and neck squamous cell carcinoma (HNSCC) mostly consist of clinical and tumor features assessed before treatment. We report a novel application of DNA methylation in peripheral blood before and after radiation therapy to further improve outcomes stratification. METHODS AND MATERIALS: Peripheral blood samples from patients with nonmetastatic HNSCC were obtained for methylation analysis 1 week before and 1 month after radiation therapy. Patients were randomized 1:1 to a Discovery Cohort or a Validation Cohort. In the Discovery Cohort, associations between genome-wide methylation change (posttreatment minus pretreatment) and recurrence-free survival (RFS) as well as overall survival (OS) were evaluated using Cox regression. A methylation risk score (MRS) was then constructed from methylation levels at the top associated sites, filtered for residing within the regulatory regions of genes expressed in cells of hematopoietic lineage. The prognostic value of MRS was separately assessed in the Discovery and Validation Cohorts. RESULTS: Between December 2013 and September 2018, 115 patients participated in this study. Human papilloma virus negative status, oral cavity cancer, gastrostomy tube insertion, and higher neutrophil count before radiation therapy were associated with shorter RFS and OS (P < .05). Genes downstream of the methylation sites comprising MRS are HIF1A, SF1, LGALS9, and FUT5, involved in hypoxia response, blood cell maturation, and immune modulation. High MRS (in the top third) was significantly associated with worse RFS (hazard ratio [HR], 7.1; 95% confidence interval [CI], 1.4-35.5; P = .016) and OS (HR, 15.9; 95% CI, 1.6-153.6; P = .017) in the Discovery Cohort, independent of the aforementioned risk factors. These findings were replicated in the Validation Cohort, for which high MRS also independently predicted worse RFS (HR, 10.2; 95%, CI 2.4-43.4; P = .002) and OS (HR, 3.7; 95% CI, 1.3-10.4; P = .015). CONCLUSIONS: We successfully trained and validated a signature of DNA methylation in peripheral blood before and after radiation therapy that stratified outcomes among patients with HNSCC, implicating the potential for genomics-tailored surveillance and consolidation treatment.
引用
- Qian DC, Ulrich BC, Peng G, et al. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood. Int J Radiat Oncol Biol Phys. 2022. PMID: 36410685. doi:10.1016/j.ijrobp.2022.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。